SK bio families to present visions to global investors at SK Bio Night

SK Inc., the investment company of SK Group, said on Tuesday that it will hold a networking event called "SK Bio Night" in the US along with its bio affiliates SK Biopharmaceuticals and SK Pharmteco.

The event, which will be held for the first time by SK Inc., on Jan. 11, in San Francisco, California, aims to introduce SK Group's global life science business portfolio for future strategic and financial partnerships.

About 100 executives from 50 investment and life science companies will be participating in the event.

SK Biopharmaceuticals CEO Lee Donghoon will stand on the podium with SK Pharmteco CEO Joerg Ahlgrimm, and SK Bio Investment Center Head Kim Yeontae--all newly appointed chiefs of SK's bio trios--for the occasion to be led by SK Vice Chairman Jang Dong-hyun.

Lee will explain the growth of SK's epilepsy treatment Cenobamate (US brand name: XCOPRI) in the global market and the strategy of building new drugs, while Kim will present SK's strategy to expand the business area beyond synthetic drugs to the biopharmaceutical sector.

Ahlgrimm will introduce SK Pharmteco's business vision, competitiveness, and operating direction as a global CDMO company.

"SK Bio Night will offer a great opportunity for the company to further grow globally not only with SK, but also with financial and strategic partners. We will preempt growth opportunities through localization of bio businesses centered on global market hubs such as the US and Europe," said Kim Yeontae, head of SK Bio Investment Center.

SK Pharmteco was established by SK in 2019 for the integrated operation of CDMO businesses in Korea, the US, and Europe, and SK Biopharmaceuticals is a company that focuses on the research and development of new drugs.

Write to Jae-Young Han at jyhan@hankyung.com